Skip to main content
    R

    Rapid Micro Biosystems Inc (RPID)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.74
    +0.09 (+13.67%)

    Market Cap: $32.65M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rapid Micro Biosystems Inc (RPID) Financials: Revenue, Profit and Cash Flow

    Updated Aug 7, 2026. Financial statements from company filings, amounts in US dollars.

    Rapid Micro Biosystems reported revenue of $33.59M for the fiscal year ended Dec 31, 2025, up 19.7% from the year before. That year, net income was -$47.12M with a net margin of -140.3%, operating cash flow was -$31.06M and free cash flow was -$31.91M. The quarter ended Jun 30, 2026 had revenue of $8.05M and net income of -$12.92M.

    Revenue and Margins

    Over the 15 years to Dec 2025, revenue grew from $16.08M, a compound annual rate of 5.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$33.59M+19.7%3.1%-141.1%-140.3%
    Dec 2024$28.05M+24.6%-0.4%-178.0%-167.2%
    Dec 2023$22.52M+31.4%-24.4%-251.2%-233.0%
    Dec 2022$17.13M-26.3%-49.8%-369.0%-354.9%
    Dec 2021$23.23M+44.5%-33.3%-203.3%-316.5%
    Dec 2020$16.08M-2.6%-50.2%-190.0%-230.6%
    Dec 2019$16.51MN/A-1.4%-112.9%-128.2%
    Dec 2011$10.97M-31.8%N/AN/AN/A
    Dec 2010$16.08MN/A0.4%N/AN/A
    Annual, fiscal years ended Dec 2010 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2011Dec 2010
    Revenue$33.59M$28.05M$22.52M$17.13M$23.23M$16.08M$16.51M$10.97M$16.08M
    Cost of revenue$32.54M$28.16M$28.00M$25.67M$30.97M$24.15M$16.75M$11.78M$16.02M
    Gross profit$1.05M-$109.00K-$5.49M-$8.54M-$7.74M-$8.07M-$234.00KN/A$59.00K
    Research and development$13.60M$14.60M$12.82M$12.87M$9.78M$6.53M$5.43M$0$0
    Operating income-$47.39M-$49.92M-$56.56M-$63.22M-$47.23M-$30.54M-$18.63MN/AN/A
    Net income-$47.12M-$46.89M-$52.47M-$60.81M-$73.52M-$37.08M-$21.17MN/AN/A
    EBITDA-$44.25M-$46.67M-$53.54M-$60.32MN/A-$29.08M-$16.87MN/AN/A
    Fiscal years ended Dec 2010 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$8.05M$8.00M$11.28M$7.84M$7.26M$7.21M$8.22M$7.60M$6.62M$5.61M$6.34M$6.14M
    Gross profit$1.21M$371.00K-$328.00K$696.00K$275.00K$404.00K$981.00K$622.00K-$189.00K-$1.52M-$172.00K-$1.63M
    Operating income-$12.32M-$13.85M-$12.21M-$11.37M-$12.15M-$11.66M-$10.23M-$12.04M-$13.38M-$14.27M-$12.19M-$14.45M
    Net income-$12.92M-$14.28M-$12.50M-$11.51M-$11.86M-$11.26M-$9.67M-$11.32M-$12.58M-$13.32M-$11.17M-$13.39M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $20.20M exceeded cash and equivalents by $170.00K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2011Dec 2010
    Total assets$74.85M$98.17M$143.45M$190.65M$241.17M$70.00M$31.69M$1.66M$2.32M
    Current assets$61.17M$80.92M$120.42M$138.58M$218.12M$62.15M$23.61MN/AN/A
    Cash and equivalents$20.03M$16.91M$24.29M$27.06M$178.39M$30.08M$12.46M$1.00K$156.00K
    Total liabilities$41.65M$22.82M$25.46M$26.48M$20.19M$45.18M$32.41M$6.84M$5.02M
    Short-term debt$1.30M$1.21M$1.13M$766.00K$10.58M$6.54M$5.35MN/AN/A
    Long-term debt$18.90M$0N/AN/AN/A$24.81M$17.81MN/A$1.75M
    Shareholder equity$33.21M$75.35M$117.99M$164.17M$220.98M-$127.01M-$725.00K-$5.17M-$2.70M
    Fiscal years ended Dec 2010 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$58.45M$62.36M$74.85M$84.41M$75.59M$85.43M$98.17M$105.84M$117.08M$127.73M$143.45M$150.16M
    Total liabilities$40.70M$41.97M$41.65M$40.08M$21.04M$19.94M$22.82M$21.47M$22.50M$21.79M$25.46M$22.38M
    Cash and equivalents$14.69M$13.81M$20.03M$18.95M$18.33M$18.91M$16.91M$22.04M$37.12M$22.43M$24.29M$23.79M
    Shareholder equity$17.75M$20.40M$33.21M$44.33M$54.55M$65.49M$75.35M$84.37M$94.59M$105.94M$117.99M$127.79M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$31.06M-$44.15M-$45.08M-$58.55M-$54.96M-$31.00M-$21.15M
    Capital expenditures$850.00K$1.36M$1.84M$6.74M$3.22M$690.00K$1.70M
    Free cash flow-$31.91M-$45.52M-$46.93M-$65.29M-$58.18M-$31.69M-$22.84M
    Dividends paidN/AN/A$186.00K$566.00KN/AN/AN/A
    Investing cash flow$14.33M$36.66M$42.15M-$93.47M-$13.29M-$15.67M-$1.70M
    Financing cash flow$19.77M$203.00K$149.00K$693.00K$216.75M$64.23M$14.87M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$12.70M-$15.06M-$3.25M-$9.05M-$9.70M-$9.06M-$9.91M-$8.60M-$10.12M-$15.53M-$9.50M-$9.71M
    Capital expenditures$223.00K$394.00K$92.00K$73.00K$366.00K$319.00K$98.00K$223.00K$459.00K$585.00K$418.00K$453.00K
    Free cash flow-$12.93M-$15.45M-$3.34M-$9.12M-$10.07M-$9.38M-$10.01M-$8.82M-$10.58M-$16.11M-$9.91M-$10.16M
    Last 12 quarters

    Frequently Asked Questions About RPID

    What is Rapid Micro Biosystems' annual revenue?

    Rapid Micro Biosystems reported revenue of $33.59M for the fiscal year ended Dec 31, 2025.

    How fast is Rapid Micro Biosystems' revenue growing?

    Revenue was up 19.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 25.2%.

    Is Rapid Micro Biosystems profitable?

    No. Rapid Micro Biosystems reported net income of -$47.12M for the fiscal year ended Dec 31, 2025, with a net margin of -140.3%.

    How much free cash flow does RPID generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$31.06M minus capital expenditures of $850.00K produced free cash flow of -$31.91M.

    How much debt does Rapid Micro Biosystems have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $18.90M, short-term debt of $1.30M and cash and equivalents of $20.03M.